Obesity development: mechanisms and treatment patterns, not a league table

Published
2026-09-23
Series
Biotech Pipeline

This first comparison covers nine selected compounds.

Companies

Article body

This first comparison covers nine selected compounds. Regulatory and company disclosures are covered through September 22, 2026; registry snapshots were collected September 23 UTC. It is a curated sample, not a comprehensive market census. The approved products establish a treatment setting against which investigational programs are developing different mechanisms, formulations and schedules.

## [Semaglutide](https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-semaglutide-overview)

Position in this account: Approved GLP-1 agonist; selected weekly injected program.

Selected design and patient setting: STEP 1: placebo control, without diabetes, 68 weeks.

Question the design addresses: Weight management in a defined population; later programs require their own assessment.

## [Tirzepatide](https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-tirzepatide-overview)

Position in this account: Approved GIP/GLP-1 agonist, weekly injection.

Selected design and patient setting: SURMOUNT-1: placebo control, without diabetes, 72 weeks.

Question the design addresses: An established dual-agonist reference.

## [Orforglipron](https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-orforglipron-overview)

Position in this account: Approved oral GLP-1 agonist.

Selected design and patient setting: ATTAIN-1: placebo control, 72-week primary weight endpoint.

Question the design addresses: Oral treatment within the approved and continuing development story.

## [Retatrutide](https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-retatrutide-overview)

Position in this account: Investigational GIP/GLP-1/glucagon agonist.

Selected design and patient setting: TRIUMPH-1: placebo control, 80-week weight endpoint plus specified subsets.

Question the design addresses: Whether broader receptor activity yields a useful efficacy/tolerability balance.

## [VK2735](https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-vk2735-overview)

Position in this account: Investigational GIP/GLP-1 agonist; injectable and oral programs.

Selected design and patient setting: VANQUISH: separate diabetes/non-diabetes populations, placebo control, 78 weeks.

Question the design addresses: Pivotal weekly treatment; maintenance experiments are separate evidence.

## [Enicepatide](https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-enicepatide-overview)

Position in this account: Investigational GIP/GLP-1 agonist, weekly injection.

Selected design and patient setting: ENITH: separate diabetes/non-diabetes studies, placebo control, 72 weeks.

Question the design addresses: Larger and longer evidence following Phase 2; component contribution in a separate combination study.

## [MariTide](https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-maridebart-cafraglutide-overview)

Position in this account: Investigational GLP-1 agonism/GIP antagonism, less frequent injections.

Selected design and patient setting: Selected Phase 3 study excludes diabetes and measures weight at 72 weeks.

Question the design addresses: Whether a different mechanism and interval support durable treatment.

## [Petrelintide](https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-petrelintide-overview)

Position in this account: Investigational amylin analog, weekly injection.

Selected design and patient setting: ZUPREME-1: placebo-controlled 28-week Phase 2; separate 40-week combination trial.

Question the design addresses: Amylin-based treatment and the incremental contribution of combination components.

## [Danuglipron](https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-danuglipron-overview)

Position in this account: Discontinued oral GLP-1 program.

Selected design and patient setting: Historical Phase 2 weight assessments at 26/32 weeks; later program-level stop.

Question the design addresses: A completed study is not evidence that development continues.

The linked overviews provide the exact registry and regulatory sources for each row. Trial duration is an endpoint time point, not a promise that a readout will occur on a particular date. A study's recruitment state also does not establish whether the medicine is approved: orforglipron is an especially important example.

Several evidence types coexist. FDA decisions establish approved uses. Sponsor announcements describe new results for retatrutide, petrelintide, enicepatide and VK2735, with differing detail and follow-up. Registry entries establish design and reported study state. This comparison does not turn a completed study or a planned endpoint into a positive finding.

The biggest comparison traps are diabetes status, treatment duration, dose escalation, discontinuation and the statistical handling of people who stop treatment. Maintenance of previously achieved loss is a different outcome from additional weight reduction. A selected 12-week maintenance cohort cannot answer the same question as a 72- or 78-week pivotal trial. Percentages are therefore kept in their individual source accounts rather than ranked here.

Safety needs the same discipline. Approved labels supply established warnings and eligible populations. Gastrointestinal events and discontinuation in sponsor reports deserve attention, but short exposure and selected responders do not establish long-term safety. This account has no common patient-level dataset for a fair adverse-event ranking.

The business comparison also differs across programs. Viking is funding several development paths with a smaller balance sheet; Zealand has received substantial partner payments; Roche, Lilly, Novo and Amgen fund broad portfolios from commercial businesses while carrying different debt obligations. The company accounts (below) retain original currencies and reporting dates. The partnership accounts (below) show who shares work and economics. Neither market size nor corporate cash is treated as a probability of clinical success.

## Company and partnership context

The compound accounts describe each developer’s reported financial resources and relevant ownership or partnership agreements. Corporate balances are not dedicated compound budgets; financing after a reporting date is distinguished from the reported balance.

[Danuglipron](https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-danuglipron-overview). [Semaglutide](https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-semaglutide-overview). [Tirzepatide](https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-tirzepatide-overview). [Orforglipron](https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-orforglipron-overview). [Retatrutide](https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-retatrutide-overview). [VK2735](https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-vk2735-overview). [Enicepatide](https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-enicepatide-overview). [Maridebart cafraglutide](https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-maridebart-cafraglutide-overview). [Petrelintide](https://tip.inventingindices.com/marketbrain-2026-09-23-biotech-petrelintide-overview).

## About this account

Published September 23, 2026. Company and regulatory disclosures are covered through September 22; trial-registry records were retrieved September 23. Earlier developments are reconstructed from dated primary sources. Registry status, sponsor-reported results and regulatory decisions are distinguished in the account. Company figures retain their reporting periods; corporate cash is not a compound-specific funding commitment.

Citations

citations[31]{marker,ticker,item,date,accession,source}:
  1,"","https://www.pfizer.com/news/press-release/press-release-detail/pfizer-provides-update-oral-glp-1-receptor-agonist",2025-04-14,"",biotech_sponsor
  2,"","https://clinicaltrials.gov/study/NCT04707313",2024-11-05,"",biotech_registry
  3,"","https://clinicaltrials.gov/study/NCT06910839",2025-08-07,"",biotech_registry
  4,"","https://content.govdelivery.com/accounts/USFDA/bulletins/2e2adc7",null,"",biotech_regulator
  5,"","https://clinicaltrials.gov/study/NCT03548935",2021-11-19,"",biotech_registry
  6,"","https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management",2023-11-08,"",biotech_regulator
  7,"","https://clinicaltrials.gov/study/NCT04184622",2025-07-24,"",biotech_registry
  8,"","https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026",null,"",biotech_regulator
  9,"","https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220934s003lbl.pdf",null,"",biotech_regulator
  10,"","https://clinicaltrials.gov/study/NCT05869903",2026-08-14,"",biotech_registry
  11,"","https://www.lilly.com/news/stories/what-to-know-about-retatrutide",null,"",biotech_sponsor
  12,"","https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-delivered-powerful-weight-loss",2026-05-21,"",biotech_sponsor
  13,"","https://investor.lilly.com/news-releases/news-release-details/lillys-triple-agonist-retatrutide-successful-two-additional",2026-07-23,"",biotech_sponsor
  14,"","https://clinicaltrials.gov/study/NCT05929066",2026-08-21,"",biotech_registry
  15,"","https://clinicaltrials.gov/study/NCT06383390",2026-08-24,"",biotech_registry
  16,"","https://ir.vikingtherapeutics.com/2026-07-29-Viking-Therapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Corporate-Update",2026-07-29,"",biotech_sponsor
  17,"","https://clinicaltrials.gov/study/NCT07104500",2025-11-24,"",biotech_registry
  18,"","https://clinicaltrials.gov/study/NCT07104383",2026-04-07,"",biotech_registry
  19,"","https://clinicaltrials.gov/study/NCT06828055",2025-10-06,"",biotech_registry
  20,"","https://www.roche.com/media/releases/med-cor-2026-09-22",2026-09-22,"",biotech_sponsor
  21,"","https://clinicaltrials.gov/study/NCT07351045",2026-09-14,"",biotech_registry
  22,"","https://clinicaltrials.gov/study/NCT07351058",2026-09-14,"",biotech_registry
  23,"","https://clinicaltrials.gov/study/NCT07589686",2026-09-09,"",biotech_registry
  24,"","https://clinicaltrials.gov/study/NCT06628362",2026-06-24,"",biotech_registry
  25,"","https://www.amgen.com/stories/2026/05/the-story-of-maridebart-cafraglutide",null,"",biotech_sponsor
  26,"","https://clinicaltrials.gov/study/NCT06858839",2026-09-17,"",biotech_registry
  27,"","https://clinicaltrials.gov/study/NCT07037433",2026-09-22,"",biotech_registry
  28,"","https://clinicaltrials.gov/study/NCT07225686",2026-09-18,"",biotech_registry
  29,"","https://www.roche.com/media/releases/med-cor-2026-03-05",2026-03-05,"",biotech_sponsor
  30,"","https://clinicaltrials.gov/study/NCT06662539",2026-03-23,"",biotech_registry
  31,"","https://clinicaltrials.gov/study/NCT06926842",2026-09-09,"",biotech_registry

Read the human-formatted version →